688180.SH
君实生物-U
SSE · Healthcare · Biotechnology · CN
CNY 34.85
−6.87%Year over year
Reported trailing growth
- Revenue
- +31.7%
- EBITDA
- —
- EBIT
- +43.8%
- EPS
- +47.0%
- Free cash flow
- +24.7%
- Operating cash flow
- +59.6%
Forward estimates
Based on analyst estimates
- Revenue
- —
- EBITDA
- —
- EPS
- —
Three-year CAGR
- Revenue
- +19.8%
- EBITDA
- +31.9%
- EBIT
- +25.3%
- Net income
- +31.7%
- EPS
- +33.1%
- Free cash flow
- +39.4%
Reported trailing growth, forward expectations and three-year compound growth rates · Data as of Mar 1, 2026